{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:26:44Z","timestamp":1773296804976,"version":"3.50.1"},"reference-count":0,"publisher":"Stichting Nase","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rhin"],"published-print":{"date-parts":[[2010,9,1]]},"abstract":"<jats:p>Objective: To assess whether delivery of fluticasone propionate using a novel bi-directional delivery device (Opt-FP) offers therapeutic benefits in patients with chronic rhinosinusitis (CRS).  Methods: A prospective, single centre, randomized, double-blind, placebo (PBO)-controlled, parallel group study was conducted in adult subjects (n=20) with CRS without nasal polyps or only cobblestoned mucosa. Subjects received Opt-FP 400 \u00b5g or placebo twice daily for 12 weeks (n=10\/group). Outcome measures included symptom scores, RSOM-31, CRS VAS, nasendoscopy, peak nasal inspiratory flow (PNIF) and magnetic resonance imaging (MRI).  Results: Endoscopy score for oedema showed a highly significant and progressive improvement (12 weeks (median scores): Opt-FP -4.0, PBO -1.0, p=0.015). PNIF increased significantly during Opt-FP treatment compared to placebo (4 weeks: p=0.006; 8 weeks: p=0.03). After 12 weeks MRI scores in the Opt-FP group improved against baseline (p=0.039) and a non-significant trend was seen versus placebo. The nasal RSOM-31 subscale was significantly improved with Opt-FP treatment (4 weeks: p&lt;0.009, 8 weeks: p&lt;0.016, 12 weeks: NS). Sense of smell, nasal discomfort and combined score were all significantly improved (p&lt;0.05). The Opt-FP was well tolerated.  Conclusions: The OptiNose breath-actuated bi-directional delivery device administering fluticasone propionate (400 \u00b5g b.i.d.) is an effective and well tolerated treatment for recalcitrant CRS.<\/jats:p>","DOI":"10.4193\/rhino09.178","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T10:33:55Z","timestamp":1641551635000},"page":"292-299","source":"Crossref","is-referenced-by-count":45,"title":["Preliminary efficacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis"],"prefix":"10.4193","volume":"48","author":[{"given":"F.S.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Djupesland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.J.","family":"Fokkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2708","container-title":["Rhinology journal"],"original-title":[],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T10:33:56Z","timestamp":1641551636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rhinologyjournal.com\/Abstract.php?id=889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9,1]]}},"URL":"https:\/\/doi.org\/10.4193\/rhino09.178","relation":{},"ISSN":["0300-0729"],"issn-type":[{"value":"0300-0729","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}